Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding Div RTS (OP:RHHVF)

464.41 +20.38 (+4.59%)
Streaming Delayed Price Updated: 3:51 PM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding Div RTS

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Roche Expects Higher FY21 Sales As Delta Variant Boosts Demand For Diagnostics ↗
Roche Holding AG (OTC: RHHBY) raised its 2021 sales forecast after posting an 8% rise in nine-month revenues, driven by demand for COVID-19 tests and the strong... 
Via Benzinga
News headline image
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial ↗
AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit ... 
Via Benzinga
News headline image
Why Are Atea Pharmaceuticals Shares Plunging Today? ↗
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate... 
Via Benzinga
News headline image
Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting ↗
The FDA has greenlit Roche Holdings AG's (OTC: RHHBY) Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with... 
Via Benzinga
News headline image
Roche's Alzheimer's Candidate Secures FDA Breakthrough Designation ↗
Roche Holdings AG's (OTC: RHHBY) gantenerumab antibody received breakthrough therapy designation from the FDA for Alzheimer's disease. Gantenerumab is... 
Via Benzinga
News headline image
Labcorp's At Home Collection Kit Gets EUA Nod For Combined COVID-19 and Flu Detection ↗
The FDA has granted Emergency Use Authorization (EUA) to Laboratory Corp of America Holdings's (NYSE: LH) combined home collection kit to detect COVID-19 and... 
Via Benzinga
News headline image
BioNTech Starts Dosing In Mid-Stage Colorectal Cancer Immunotherapy Trial ↗
BioNTech SE (NASDAQ: BNTX) has dosed the first patient with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in Phase 2 clinical trial... 
Via Benzinga
News headline image
Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holdings AG (OTC: RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (... 
Via Benzinga
News headline image
Glaxo - Vir Biotech's COVID Treatment Approved In Japan ↗
Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19... 
Via Benzinga
News headline image
Acceleron In Advanced $11B Buyout Talks: Bloomberg ↗
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is... 
Via Benzinga
News headline image
Roche Builds Case For Evrysdi Benefits In Younger Spinal Muscular Atrophy Patients ↗
Roche Holding AG (OTC: RHHBY) has highlighted new data for its oral spinal muscular atrophy (SMA) treatment Evrysdi, showing its benefits when given to pre-... 
Via Benzinga
News headline image
WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access ↗
The World Health Organization (WHO) has supported another COVID-19 therapeutic but urged the related companies and governments to address the high price and limited... 
Via Benzinga
News headline image
Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know ↗
Biogen Inc's (NASDAQ: BIIB) Spinraza (nusinersen), spinal muscular atrophy (SMA) drug launched in early 2017, faces new competition from Roche Holdings AG's... 
Via Benzinga
News headline image
Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer ↗
Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating... 
Via Benzinga
News headline image
Roche Beefs Up PCR-Test Portfolio With TIB Molbiol Acquisition ↗
Roche Holdings AG (OTC: RHHBY) has agreed to acquire TIB Molbiol Group for an undisclosed amount. The deal is expected to close in Q4 of 2021. The... 
Via Benzinga
News headline image
MacroGenics' Cancer Drug Margenza Flops On Overall Survival Analysis ↗
MacroGenics Inc (NASDAQ: MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a head-to-head matchup with breast... 
Via Benzinga
News headline image
Adaptimmune Stock Moves Higher On Cancer Deal With Genentech ↗
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC:... 
Via Benzinga
News headline image
Roche's Spark Therapeutics, NeuExcell Join Forces To Develop Huntington's Disease Gene Therapy ↗
Privately-held NeuExcell Therapeutics has collaborated with Spark Therapeutics to develop a treatment for Huntington's Disease (HD). Spark... 
Via Benzinga
News headline image
See Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate ↗
AC Immune SA (NASDAQ: ACIU) and its collaborating partner Genentech, part of Roche Holdings AG (OTC: RHHBY), have announced topline data from Phase... 
Via Benzinga
News headline image
After Bladder Cancer, Roche Pulls Breast Cancer Indication For Tecentriq In US ↗
Following a consultation from the FDA, Roche Holdings AG (OTC: RHHBY) has decided to withdraw its immunotherapy, Tecentriq (atezolizumab), to treat a type of... 
Via Benzinga
News headline image
Shape Therapeutics, Roche Form $3B RNA Editing Collaboration ↗
Shape Therapeutics Inc announced a multi-target strategic collaboration and license agreement with Roche Holding AG (OTC: RHHBY) for RNA editing technology.... 
Via Benzinga
News headline image
UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail ↗
The U.K. drug regulator has approved an antibody cocktail developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holding AG (OTC: RHHBY) to prevent... 
Via Benzinga
News headline image
Roche's Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage ↗
Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization for critically ill COVID-19 patients after... 
Via Benzinga
News headline image
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer ↗
AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3... 
Via Benzinga
News headline image
Genentech's Polivy Plus R-CHP Shows Prolonged Survival In Newly Diagnosed DLBCL Patients ↗
Genentech, a member of Roche Holdings AG (OTC: RHHBY), announced that the pivotal Phase 3 POLARIX trial met its primary endpoint in people with previously... 
Via Benzinga
News headline image
Billionaire Masayoshi Son's SoftBank Claims $5B Stake In Roche: Bloomberg ↗
SoftBank Group Corp (OTC: SFTBF) has quietly acquired a $5 billion stake in Roche Holdings AG (OTC: RHHBF), making it one of the largest investors of the Roche,... 
Via Benzinga
News headline image
Roche's Tecentriq As Adjuvant Treatment Under Priority Review With FDA For Early Lung Cancer ↗
The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) Tecentriq (atezolizumab), as adjuvant treatment for... 
Via Benzinga
News headline image
FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis ↗
Following the June update that 
Via Benzinga
News headline image
Roche's Faricimab US Application For Ocular Diseases Under Priority Review ↗
The FDA has accepted Roche Holding AG's (OTC: RHHBY) Biologics License Application seeking approval for faricimab in neovascular of wet age-related macular... 
Via Benzinga
News headline image
Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings ↗
Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate. Data: 49... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.